NSC
NORFOLK SOUTHERN CORP
NORFOLK SOUTHERN CORP (NSC) Stock News
The latest NSC headlines and market coverage — 1 recent story, updated throughout the day.
- Zacks Investment Research·
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.